2-(1-Ethenylpyrrolidin-2-yl)but-3-enoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-(1-Ethenylpyrrolidin-2-yl)but-3-enoic acid
• 英文别名: 2-(1-ethenylpyrrolidin-2-yl)but-3-enoic acid
• 化学式: C₁₀H₁₅NO₂
• 分子量: 181.23
• InChiKey: WBAHVSUJWOCMFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] COCRYSTALS OF (R)-BACLOFEN<br/>[FR] COCRISTAUX DE (R)-BACLOFÈNE
  申请人：ZAKL FARMACEUTYCZNE POLPHARMA S A

  公开号：WO2020141141A1

  公开（公告）日：2020-07-09

  The invention relates to novel cocrystals of (R)-Baclofen and processes for preparation thereof, and in particular to cocrystals of (R)-Baclofen with cinnamic acid, benzoic acid, salicylic acid and ferulic acid. It also refers to pharmaceutical compositions containing said cocrystals and to a use of said cocrystals or pharmaceutical compositions for the treatment of a disease or disorder selected from spasticity due to multiple sclerosis, spinal cord injury or cerebral palsy, and alcoholism.

  该发明涉及(R)-巴氯芬的新型共晶及其制备方法，特别是(R)-巴氯芬与肉桂酸、苯甲酸、水杨酸和香豆酸的共晶。还涉及含有上述共晶的药物组合物，以及利用该共晶或药物组合物治疗由于多发性硬化症、脊髓损伤或脑瘫引起的痉挛和酗酒等疾病或障碍的用途。
• COCRYSTALS OF APREMILAST
  申请人：Zaklady Farmaceutyczne Polpharma SA

  公开号：EP3339292A1

  公开（公告）日：2018-06-27

  The invention relates to cocrystals of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]acetamide (Apremilast) with caffeine (APM-CAF) and 4-hydroxybenzoic acid (APM-4HB). It also refers to pharmaceutical compositions and dosage forms comprising said cocrystals. The invention also concerns said pharmaceutical compositions or dosage forms for use in a method of treating a disease or disorder defined in the claims. Finally, the invention pertains to the use of said cocrystals for the preparation of pharmaceutical compositions and dosage forms.

  本发明涉及 N-[2-[(1S)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙基]-1,3-二氧代-2,3-二氢-1H-异吲哚-4-基]乙酰胺（Apremilast）与咖啡因（APM-CAF）和 4-羟基苯甲酸（APM-4HB）的共晶体。本发明还涉及包含上述共晶体的药物组合物和剂型。本发明还涉及上述药物组合物或剂型，用于治疗权利要求中定义的疾病或紊乱。最后，本发明还涉及使用所述球晶体制备药物组合物和剂型。
• COCRYSTALS OF (R)-BACLOFEN
  申请人：Zaklady Farmaceutyczne "Polpharma" S.A.

  公开号：EP3674287A1

  公开（公告）日：2020-07-01

  The invention relates to novel cocrystals of (R)-Baclofen and processes for preparation thereof, and in particular to cocrystals of (R)-Baclofen with cinnamic acid, benzoic acid, salicylic acid and ferulic acid. It also refers to pharmaceutical compositions containing said cocrystals and to a use of said cocrystals or pharmaceutical compositions for the treatment of a disease or disorder selected from spasticity due to multiple sclerosis, spinal cord injury or cerebral palsy, and alcoholism.

  本发明涉及(R)-巴氯芬的新型共晶体及其制备工艺，特别是(R)-巴氯芬与肉桂酸、苯甲酸、水杨酸和阿魏酸的共晶体。它还指含有所述共晶体的药物组合物，以及所述共晶体或药物组合物用于治疗选自多发性硬化症、脊髓损伤或脑瘫引起的痉挛和酗酒的疾病或紊乱的用途。
• CRYSTALLINE FORMS OF BARICITINIB
  申请人：Zaklady Farmaceutyczne "Polpharma" S.A.

  公开号：EP3771715A1

  公开（公告）日：2021-02-03

  The invention relates to novel crystalline forms of baricitinib i.e. PPH form I and PPH form II and processes for preparation thereof. It also refers to pharmaceutical compositions containing said crystalline forms and to a use of said crystalline forms or pharmaceutical compositions for the treatment of rheumatoid arthritis.

  本发明涉及巴利替尼的新型结晶形式，即 PPH 形式 I 和 PPH 形式 II 及其制备工艺。本发明还涉及含有上述结晶形式的药物组合物，以及上述结晶形式或药物组合物治疗类风湿性关节炎的用途。
• LOW HYGROSCOPIC AMORPHOUS FORM OF BARICITINIB
  申请人：Zaklady Farmaceutyczne "Polpharma" S.A.

  公开号：EP3771716A1

  公开（公告）日：2021-02-03

  The invention relates to a low hygroscopic amorphous form of baricitinib and process for preparation thereof. It also refers to a pharmaceutical composition containing said amorphous form and to a use of said low hygroscopic amorphous form or pharmaceutical composition containing it for the treatment of rheumatoid arthritis.

  本发明涉及巴利替尼的低吸湿性无定形形式及其制备工艺。本发明还涉及一种含有上述无定形形式的药物组合物，以及上述低吸湿性无定形形式或含有该无定形形式的药物组合物在治疗类风湿性关节炎中的用途。